P1, N=24, Recruiting, AstraZeneca

All the pyrrolobenzodiazepines tested - SJG136, SGD-1882, SG2057, and SG3199 - were substrates of P-gp, ABCG2, and MRP1. The modified anthracyclines nemorubicin and its metabolite PNU-159682 were poorly transported by both ABCB1 and ABCG2 and displayed nanomolar to picomolar toxicity. Further, we found that the efficacy of the FDA-approved ADC mirvetuximab soravtansine, with DM4 as the toxic payload, was decreased in cell lines expressing P-gp... Several commonly used ADC payloads can be transported by ABC transporters, potentially leading to transporter-mediated drug resistance in patients. Future ADCs should be developed using payloads that are not ABC transporter substrates.

Finally, any-grade ocular adverse events (OAEs) are particularly common in patients during MIRV treatment, arising in 125 (57 %); grade ≥3 in 34 (16 %), most frequently, blurred vision (18 [8 %]), keratopathy (21 [10 %]), cataract (11 [5 %]), and dry eye (8 [4 %]); however, fortunately, over 90 % with OAEs had either full resolution or documented final grade 1 or better. The current review also discusses OAE, based on its high incidence, frequent cause responsible to dose reduction and delaying therapy with impacting 11-35 % of patients and of the most importance, relative unfamiliarity to most gynecological oncologists in the routine clinical practice.

P2, N=240, Recruiting, Genmab | Not yet recruiting --> Recruiting

P3, N=1100, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

P1, N=156, Recruiting, Shanghai Institute Of Biological Products | Not yet recruiting --> Recruiting

P3, N=528, Recruiting, Genmab | Not yet recruiting --> Recruiting

P1/2, N=0, Withdrawn, Bio-Thera Solutions | N=170 --> 0 | Not yet recruiting --> Withdrawn

P1, N=216, Completed, Bio-Thera Solutions | Recruiting --> Completed | Trial primary completion date: Dec 2024 --> Dec 2025

P1, N=170, Recruiting, Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

FZEC showed promising antitumor activity, and the observed adverse events were generally manageable, with the exception of ILD, in patients with PROC.

Approximately half of the ovarian cancer patients in this multicenter Polish cohort demonstrated FOLR1 positivity. Although this prevalence is lower than that reported in high-grade serous carcinoma cohorts, it likely reflects histological heterogeneity and methodological differences between studies. These findings provide the first population-based evidence from Poland and support the implementation of FOLR1 testing to guide access to mirvetuximab soravtansine. Further research integrating clinical and molecular data is warranted to validate these results and assess implications for cost-effectiveness and patient outcomes.